Citations (46)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Rory M. Shallis, Nora Chokr, Maximilian Stahl, Alexander B. Pine & Amer M. Zeidan. (2018) Immunosuppressive therapy in myelodysplastic syndromes: a borrowed therapy in search of the right place. Expert Review of Hematology 11:9, pages 715-726.
Read now
Read now
Lisa Pleyer & Richard Greil. (2015) Digging deep into “dirty” drugs – modulation of the methylation machinery. Drug Metabolism Reviews 47:2, pages 252-279.
Read now
Read now
Stavroula Giannouli & Michael Voulgarelis. (2014) A comprehensive review of myelodysplastic syndrome patients with autoimmune diseases. Expert Review of Clinical Immunology 10:12, pages 1679-1688.
Read now
Read now
Naomi Galili & Azra Raza. (2010) Pharmacotherapy of myelodysplastic syndromes. Expert Opinion on Pharmacotherapy 11:11, pages 1889-1899.
Read now
Read now
Tony Navas, Li Zhou, Myka Estes, Edwin Haghnazari, Aaron N. Nguyen, Yongkai Mo, Perry Pahanish, Mani Mohindru, Tim Cao, Linda S. Higgins, Leonidas C. Platanias, Alan List & Amit Verma. (2008) Inhibition of p38α MAPK disrupts the pathological loop of proinflammatory factor production in the myelodysplastic syndrome bone marrow microenvironment. Leukemia & Lymphoma 49:10, pages 1963-1975.
Read now
Read now
Naomi Galili & Azra Raza. (2006) Immunomodulatory drugs in myelodysplastic syndromes. Expert Opinion on Investigational Drugs 15:7, pages 805-813.
Read now
Read now
Roberto Stasi, Sergio Amadori, Adrian C Newland & Drew Provan. (2005) Infliximab chimeric antitumor necrosis factor-α monoclonal antibody as potential treatment for myelodysplastic syndromes. Leukemia & Lymphoma 46:4, pages 509-516.
Read now
Read now
Articles from other publishers (39)
Bruno Fattizzo, Fabio Serpenti, Wilma Barcellini & Chiara Caprioli. (2021) Hypoplastic Myelodysplastic Syndromes: Just an Overlap Syndrome?. Cancers 13:1, pages 132.
Crossref
Crossref
Claudio Fozza. (2019) Retuning the immune system in myelodysplastic syndromes: from immunomodulatory approaches to vaccination strategies and non myeloablative hemopoietic cell transplant. Critical Reviews in Oncology/Hematology 133, pages 112-119.
Crossref
Crossref
Aditi Shastri & Amit K Verma. (2018) Eltrombopag reduces clinically relevant thrombocytopenic events in higher risk MDS and AML. The Lancet Haematology 5:1, pages e6-e7.
Crossref
Crossref
Xiaoxi Zhou, Zhuoya Li & Jianfeng Zhou. (2017) Tumor necrosis factor α in the onset and progression of leukemia. Experimental Hematology 45, pages 17-26.
Crossref
Crossref
Claudio Fozza, Valeria Crobu, Maria Antonia Isoni & Fausto Dore. (2016) The immune landscape of myelodysplastic syndromes. Critical Reviews in Oncology/Hematology 107, pages 90-99.
Crossref
Crossref
Ilaria Marech, Christian Leporini, Michele Ammendola, Mariangela Porcelli, Cosmo Damiano Gadaleta, Emilio Russo, Giovambattista De Sarro & Girolamo Ranieri. (2016) Classical and non-classical proangiogenic factors as a target of antiangiogenic therapy in tumor microenvironment. Cancer Letters 380:1, pages 216-226.
Crossref
Crossref
Erinn B. Rankin, Anupama Narla, Joseph K. Park, Shuo Lin & Kathleen M. Sakamoto. (2015) Biology of the bone marrow microenvironment and myelodysplastic syndromes. Molecular Genetics and Metabolism 116:1-2, pages 24-28.
Crossref
Crossref
Anca Prica & Rena Buckstein. (2015) Myelodysplastic Syndrome Successfully Treated With Adalimumab. Journal of Clinical Oncology 33:2, pages e4-e6.
Crossref
Crossref
Yi Lin, Guohua Li, Wenjie Zheng, Xinping Tian & Fengchun Zhang. (2014) Behcet's disease associated with malignancy: a report of 41 Chinese cases. International Journal of Rheumatic Diseases 17:4, pages 459-465.
Crossref
Crossref
Lohith Bachegowda, Oleg Gligich, Ionnis Mantzaris, Carolina Schinke, Dale Wyville, Tatiana Carrillo, Ira Braunschweig, Ulrich Steidl & Amit Verma. (2013) Signal transduction inhibitors in treatment of myelodysplastic syndromes. Journal of Hematology & Oncology 6:1.
Crossref
Crossref
Thorsten Braun & Pierre Fenaux. (2013) Myelodysplastic Syndromes (MDS) and autoimmune disorders (AD): Cause or consequence?. Best Practice & Research Clinical Haematology 26:4, pages 327-336.
Crossref
Crossref
Claudio Fozza & Maurizio Longinotti. (2013) The role of T-cells in the pathogenesis of myelodysplastic syndromes: Passengers and drivers. Leukemia Research 37:2, pages 201-203.
Crossref
Crossref
Yusuke KAWASAKI, Hiroaki TERAJIMA, Shugo UEDA, Akiko FUKUNAGA & Masato YAGITA. (2013) A Case of Intestinal Beh^|^ccedil;etʼs Disease with Perforated Ulcer Concurrent with Myelodysplastic Syndrome and Trisomy 8. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association) 74:6, pages 1547-1551.
Crossref
Crossref
Claudio Fozza & Maurizio Longinotti. (2012) Are T‐cell dysfunctions the other side of the moon in the pathogenesis of myelodysplastic syndromes?. European Journal of Haematology 88:5, pages 380-387.
Crossref
Crossref
Shayne Cox GadSatadal Chatterjee & Shobhan Gaddameedhi. 2010. Pharmaceutical Sciences Encyclopedia. Pharmaceutical Sciences Encyclopedia.
Bartosz Malisiewicz, Carla Murer, Jana Pachlopnik Schmid, Lars E. French, Peter Schmid-Grendelmeier & Alexander A. Navarini. (2011) Eosinophilia during Psoriasis Treatment with TNF Antagonists. Dermatology 223:4, pages 311-315.
Crossref
Crossref
Antonio M. Risitano. (2011) Immunosuppressive therapies in the management of immune-mediated marrow failures in adults: where we stand and where we are going. British Journal of Haematology 152:2, pages 127-140.
Crossref
Crossref
Konstantinos Anargyrou, Theodoros P. Vassilakopoulos, Maria K. Angelopoulou & Evangelos Terpos. (2010) Incorporating novel agents in the treatment of myelodysplastic syndromes. Leukemia Research 34:1, pages 6-17.
Crossref
Crossref
Lisa Pleyer, Daniel Neureiter, Victoria Faber & Richard Greil. 2010. Chronic Myeloid Neoplasias and Clonal Overlap Syndromes. Chronic Myeloid Neoplasias and Clonal Overlap Syndromes
153
222
.
Naomi Galili & Azra Raza. (2009) Clinical implications of gene expression profiling in myelodysplastic syndromes: Recognition of ribosomal and translational gene dysregulation and development of predictive assays. Best Practice & Research Clinical Haematology 22:2, pages 223-237.
Crossref
Crossref
Denise M. Oliansky, Joseph H. Antin, John M. Bennett, H. Joachim Deeg, Christin Engelhardt, Kathleen V. Heptinstall, Marcos de Lima, Steven D. Gore, Ronald G. Potts, Lewis R. Silverman, Roy B. Jones, Philip L. McCarthyJr.Jr. & Theresa Hahn. (2009) The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Therapy of Myelodysplastic Syndromes: An Evidence-Based Review. Biology of Blood and Marrow Transplantation 15:2, pages 137-172.
Crossref
Crossref
Hiroyuki Takamatsu, J. Luis Espinoza, Xuzhang Lu, Zhirong Qi, Katsuya Okawa & Shinji Nakao. (2009) Anti-Moesin Antibodies in the Serum of Patients with Aplastic Anemia Stimulate Peripheral Blood Mononuclear Cells to Secrete TNF-α and IFN-γ. The Journal of Immunology 182:1, pages 703-710.
Crossref
Crossref
Li Zhou & Amit Verma. 2009. Molecular Basis of Hematopoiesis. Molecular Basis of Hematopoiesis
231
252
.
Florian Nolte & Wolf-K. Hofmann. (2008) Myelodysplastic syndromes: molecular pathogenesis and genomic changes. Annals of Hematology 87:10, pages 777-795.
Crossref
Crossref
E.R. Brown, K.A. Charles, S.A. Hoare, R.L. Rye, D.I. Jodrell, R.E. Aird, R. Vora, U. Prabhakar, M. Nakada, R.E. Corringham, M. DeWitte, C. Sturgeon, D. Propper, F.R. Balkwill & J.F. Smyth. (2008) A clinical study assessing the tolerability and biological effects of infliximab, a TNF-α inhibitor, in patients with advanced cancer. Annals of Oncology 19:7, pages 1340-1346.
Crossref
Crossref
J. K. Ahn, H.-S. Cha, E.-M. Koh, S.-H. Kim, Y. G. Kim, C.-K. Lee & B. Yoo. (2008) Behcet's disease associated with bone marrow failure in Korean patients: clinical characteristics and the association of intestinal ulceration and trisomy 8. Rheumatology 47:8, pages 1228-1230.
Crossref
Crossref
Eva Hellström-Lindberg & Luca Malcovati. (2008) Supportive care, growth factors, and new therapies in myelodysplastic syndromes. Blood Reviews 22:2, pages 75-91.
Crossref
Crossref
Derek L. Stirewalt, Andrew J. Mhyre, Mario Marcondes, Era Pogosova-Agadjanyan, Nissa Abbasi, Jerald P. Radich & H. Joachim Deeg. (2008) Tumour necrosis factor-induced gene expression in human marrow stroma: clues to the pathophysiology of MDS?. British Journal of Haematology 140:4, pages 444-453.
Crossref
Crossref
Seth J. Corey, Mark D. Minden, Dwayne L. Barber, Hagop Kantarjian, Jean C. Y. Wang & Aaron D. Schimmer. (2007) Myelodysplastic syndromes: the complexity of stem-cell diseases. Nature Reviews Cancer 7:2, pages 118-129.
Crossref
Crossref
Tony A. NavasMani MohindruMyka EstesJing Ying MaLubomir SokolPerry PahanishSimrit ParmarEdwin HaghnazariLi ZhouRobert CollinsIrene KerrAaron N. NguyenYin XuLeonidas C. PlataniasAlan A. ListLinda S. HigginsAmit Verma. (2006) Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors. Blood 108:13, pages 4170-4177.
Crossref
Crossref
Frances Balkwill. (2006) TNF-α in promotion and progression of cancer. Cancer and Metastasis Reviews 25:3, pages 409-416.
Crossref
Crossref
Mikkael A. Sekeres & Alan List. (2006) Immunomodulation in myelodysplastic syndromes. Best Practice & Research Clinical Haematology 19:4, pages 757-767.
Crossref
Crossref
Anna Boula, Michael Voulgarelis, Stavroula Giannouli, George Katrinakis, Maria Psyllaki, Charalambos Pontikoglou, Fotini Markidou, George D. Eliopoulos & Helen A. Papadaki. (2006) Effect of cA2 Anti–Tumor Necrosis Factor-α Antibody Therapy on Hematopoiesis of Patients with Myelodysplastic Syndromes. Clinical Cancer Research 12:10, pages 3099-3108.
Crossref
Crossref
Lodovico Balducci. (2006) Transfusion independence in patients with myelodysplastic syndromes. Cancer 106:10, pages 2087-2094.
Crossref
Crossref
Min-Kyoung KimJae-Lyun LeeHee Soon ChoSung Hwa BaeHun Mo RyooKyung Hee LeeMyung Soo Hyun. (2006) The Hematologic Response to Anti-apoptotic Cytokine Therapy: Results of Pentoxifylline, Ciprofloxacin, and Dexamethasone Treatment for Patients with Myelodysplastic Syndrome. Journal of Korean Medical Science 21:1, pages 40.
Crossref
Crossref
Magda Elkabani & Alan F List. (2006) Management of Transfusion-Dependent Myelodysplastic Syndromes. American Journal of Cancer 5:2, pages 71-80.
Crossref
Crossref
Efstratios Katsoulidis, Yongzhong Li, Patrick Yoon, Antonella Sassano, Jessica Altman, Padma Kannan-Thulasiraman, Lakshmi Balasubramanian, Simrit Parmar, John Varga, Martin S. Tallman, Amit Verma & Leonidas C. Platanias. (2005) Role of the p38 Mitogen-Activated Protein Kinase Pathway in Cytokine-Mediated Hematopoietic Suppression in Myelodysplastic Syndromes. Cancer Research 65:19, pages 9029-9037.
Crossref
Crossref
Azra Raza & Naomi Galili. (2005) Lenalidomide for myelodysplastic syndromes: finally, hope not hype. Nature Clinical Practice Oncology 2:8, pages 390-391.
Crossref
Crossref
A. Candoni, A. Raza, F. Silvestri, L. Lisak, N. Galili, M. Mumtaz, F. Kikic & R. Fanin. (2005) Response rate and survival after thalidomide-based therapy in 248 patients with myelodysplastic syndromes. Annals of Hematology 84:7, pages 479-481.
Crossref
Crossref